Oncotype DX Breast Recurrence Score

The Oncotype DX® test provides significant value in clinical practice

For node-positive, early-stage HR+ HER2- breast cancer patients

The Oncotype DX Breast Recurrence Score® result is predictive of chemotherapy benefit in your postmenopausal patients with HR+, HER2-, node-positive (1-3 positive nodes), early-stage, invasive breast cancer as demonstrated by the SWOG-8814 study.1 Data from SWOG-8814 and the RxPONDER randomized prospective trial show that a substantial proportion of these patients can be spared chemotherapy.1,7


CT benefit expressed in percentage points based on probability of distant recurrence (N0) or distant recurrence-free interval (N1) with/without CT at 5 years. No CT benefit is considered for an absolute benefit <1%.
*The benefit of chemotherapy for premenopausal N1 patients with RS® results 26-100 has not been formally assessed in a randomized study. The benefit derived from chemotherapy was significant for RS® results 0-13 and 14-25 in the RxPONDER study and it is inferred to be substantial for patients with RS® 26-100.

Use of the Oncotype DX test may reduce the risk of overtreatment with chemotherapy in node-positive HR+, HER2- early-stage breast cancer1,6-7

Average chemotherapy treatment rates without genomic testing are in the range of 70% for this patient population8-9. RxPONDER demonstrated that many of these patients may be overtreated6-7, and the Oncotype DX test can help make informed treatment decisions.




Nodal status, despite being of prognostic value, does not predict the Recurrence Score result and the underlying tumour biology4


Overall, 566,438 tumour specimens with known nodal status were examined by the Genomic Health laboratory (now Exact Sciences) from February 2004 to August 20174


In summary, adjuvant chemotherapy may be guided with the Oncotype DX test to identify the majority of node-positive patients (with up to 3 positive nodes) who will not benefit from the addition of chemotherapy.1,6-7



The Oncotype DX Breast Recurrence Score* test should be used for:

  • All patients for whom chemotherapy can potentially be spared
  • All patients for whom chemotherapy can potentially be life-saving
*For early stage, HR+, HER2- patients with up to 3 involved nodes

Contact Us